Do analysts recommend BLRX or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 32,297.41%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BLRX or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -502.08% -34.80% -18.27% GeoVax Labs N/A -743.64% -394.74%

Does the media refer more to BLRX or GOVX?

In the previous week, BioLineRx and BioLineRx both had 4 articles in the media. GeoVax Labs' average media sentiment score of 0.60 beat BioLineRx's score of 0.60 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, GOVX or PHIO?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs N/A N/A -$21.47M -$11.34 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A

Is GOVX or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% Phio Pharmaceuticals N/A -87.41% -79.76%

Which has higher valuation & earnings, GOVX or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs N/A N/A -$21.47M -$11.34 N/A PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A

Is GOVX or PDSB more profitable?

PDS Biotechnology's return on equity of -708.18% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% PDS Biotechnology N/A -708.18% -136.50%

Does the media prefer GOVX or PDSB?

In the previous week, PDS Biotechnology had 7 more articles in the media than GeoVax Labs. MarketBeat recorded 11 mentions for PDS Biotechnology and 4 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.60 beat PDS Biotechnology's score of 0.42 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PDS Biotechnology 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, GOVX or FBLG?

FibroBiologics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs N/A N/A -$21.47M -$11.34 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is GOVX or FBLG more profitable?

FibroBiologics' return on equity of -536.78% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% FibroBiologics N/A -536.78% -225.12%

Does the media refer more to GOVX or FBLG?

In the previous week, GeoVax Labs and GeoVax Labs both had 4 articles in the media. GeoVax Labs' average media sentiment score of 0.60 beat FibroBiologics' score of 0.22 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, GOVX or AEON?

AEON Biopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GeoVax Labs N/A N/A -$21.47M -$11.34 N/A AEON Biopharma N/A N/A -$36.63M -$4.42 N/A

Is GOVX or AEON more profitable?

AEON Biopharma's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets GeoVax Labs N/A -743.64% -394.74% AEON Biopharma N/A N/A -994.63%

Does the media prefer GOVX or AEON?

In the previous week, GeoVax Labs had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 4 mentions for GeoVax Labs and 2 mentions for AEON Biopharma. GeoVax Labs' average media sentiment score of 0.60 beat AEON Biopharma's score of -0.59 indicating that GeoVax Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

GeoVax Labs (GOVX) Competitors

$0.46 0.00 (-0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$0.47 +0.01 (+1.08%)

As of 07:55 PM Eastern

Compare

GOVX vs. BLRX, PHIO, PDSB, FBLG, and AEON

Should you buy GeoVax Labs stock or one of its competitors? GeoVax Labs's main competitors and comparable companies include BioLineRx (BLRX), Phio Pharmaceuticals (PHIO), PDS Biotechnology (PDSB), FibroBiologics (FBLG), and AEON Biopharma (AEON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GeoVax Labs compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

BioLineRx has higher revenue and earnings than GeoVax Labs. BioLineRx is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.32	-$1.17M	-$1.69	N/A
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A

BioLineRx has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.66, indicating that its stock price is 266% more volatile than the broader market.

In the previous week, BioLineRx and BioLineRx both had 4 articles in the media. GeoVax Labs' average media sentiment score of 0.60 beat BioLineRx's score of 0.60 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 32,297.41%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts plainly believe GeoVax Labs is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
GeoVax Labs	N/A	-743.64%	-394.74%

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

GeoVax Labs beats BioLineRx on 7 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to Phio Pharmaceuticals?

GeoVax Labs (NASDAQ:GOVX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

GeoVax Labs has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

GeoVax Labs currently has a consensus target price of $150.00, indicating a potential upside of 32,297.41%. Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,259.22%. Given GeoVax Labs' higher probable upside, equities research analysts clearly believe GeoVax Labs is more favorable than Phio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

In the previous week, GeoVax Labs had 3 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 4 mentions for GeoVax Labs and 1 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.93 beat GeoVax Labs' score of 0.60 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
GeoVax Labs	Positive
Phio Pharmaceuticals	Positive

Phio Pharmaceuticals' return on equity of -87.41% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Phio Pharmaceuticals beats GeoVax Labs on 9 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to PDS Biotechnology?

GeoVax Labs (NASDAQ:GOVX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, PDS Biotechnology had 7 more articles in the media than GeoVax Labs. MarketBeat recorded 11 mentions for PDS Biotechnology and 4 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.60 beat PDS Biotechnology's score of 0.42 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

PDS Biotechnology's return on equity of -708.18% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
PDS Biotechnology	N/A	-708.18%	-136.50%

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 32,297.41%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 2,951.88%. Given GeoVax Labs' higher possible upside, analysts plainly believe GeoVax Labs is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PDS Biotechnology is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

Summary

PDS Biotechnology beats GeoVax Labs on 8 of the 13 factors compared between the two stocks.

How does GeoVax Labs compare to FibroBiologics?

GeoVax Labs (NASDAQ:GOVX) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

FibroBiologics' return on equity of -536.78% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
FibroBiologics	N/A	-536.78%	-225.12%

GeoVax Labs has a beta of 3.66, meaning that its share price is 266% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

6.1% of GeoVax Labs shares are owned by institutional investors. 0.7% of GeoVax Labs shares are owned by company insiders. Comparatively, 7.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

FibroBiologics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

In the previous week, GeoVax Labs and GeoVax Labs both had 4 articles in the media. GeoVax Labs' average media sentiment score of 0.60 beat FibroBiologics' score of 0.22 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GeoVax Labs presently has a consensus price target of $150.00, indicating a potential upside of 32,297.41%. FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 4,434.16%. Given GeoVax Labs' higher possible upside, research analysts plainly believe GeoVax Labs is more favorable than FibroBiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

FibroBiologics beats GeoVax Labs on 7 of the 12 factors compared between the two stocks.

How does GeoVax Labs compare to AEON Biopharma?

GeoVax Labs (NASDAQ:GOVX) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, GeoVax Labs had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 4 mentions for GeoVax Labs and 2 mentions for AEON Biopharma. GeoVax Labs' average media sentiment score of 0.60 beat AEON Biopharma's score of -0.59 indicating that GeoVax Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 0.7% of GeoVax Labs shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GeoVax Labs currently has a consensus price target of $150.00, indicating a potential upside of 32,297.41%. AEON Biopharma has a consensus price target of $1.33, indicating a potential upside of 307.87%. Given GeoVax Labs' higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

AEON Biopharma's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-743.64%	-394.74%
AEON Biopharma	N/A	N/A	-994.63%

GeoVax Labs has a beta of 3.66, meaning that its share price is 266% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

AEON Biopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

Summary

AEON Biopharma beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

Get GeoVax Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOVX vs. The Competition

Export

Metric	GeoVax Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.43M	$3.86B	$7.16B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-0.04	14.11	272.69	25.25
Price / Sales	N/A	1,263.93	594.77	72.00
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	0.21	15.13	10.33	6.20
Net Income	-$21.47M	-$22.82M	$3.49B	$358.27M
7 Day Performance	-4.16%	-4.31%	-3.29%	-2.35%
1 Month Performance	-39.87%	0.39%	-0.26%	-2.61%
1 Year Performance	-97.42%	38.28%	17.32%	8.08%

GeoVax Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOVX GeoVax Labs	2.0357 of 5 stars	$0.46 -0.5%	$150.00 +32,297.4%	-97.3%	$3.43M	N/A	N/A	10	Short Interest Increase Gap Up
BLRX BioLineRx	0.6171 of 5 stars	$2.67 flat	N/A	-39.4%	$12.95M	$1.18M	N/A	40	News Coverage
PHIO Phio Pharmaceuticals	4.3067 of 5 stars	$1.08 flat	$14.00 +1,196.3%	-59.1%	$12.55M	N/A	N/A	10	News Coverage
PDSB PDS Biotechnology	2.7914 of 5 stars	$0.22 flat	$9.00 +3,990.9%	-74.4%	$12.31M	N/A	N/A	20	Options Volume Analyst Revision
FBLG FibroBiologics	2.1249 of 5 stars	$1.81 flat	$73.00 +3,933.1%	-84.1%	$12.05M	N/A	N/A	10	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOVX) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeoVax Labs (GOVX) Competitors

GOVX vs. BLRX, PHIO, PDSB, FBLG, and AEON

How does GeoVax Labs compare to BioLineRx?

Summary

How does GeoVax Labs compare to Phio Pharmaceuticals?

Summary

How does GeoVax Labs compare to PDS Biotechnology?

Summary

How does GeoVax Labs compare to FibroBiologics?

Summary

How does GeoVax Labs compare to AEON Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeoVax Labs (GOVX) Competitors

GOVX vs. BLRX, PHIO, PDSB, FBLG, and AEON

How does GeoVax Labs compare to BioLineRx?

Which has preferable valuation and earnings, BLRX or GOVX?

Which has more volatility and risk, BLRX or GOVX?

Does the media refer more to BLRX or GOVX?

Do analysts recommend BLRX or GOVX?

Is BLRX or GOVX more profitable?

Do insiders & institutionals hold more shares of BLRX or GOVX?

Summary

How does GeoVax Labs compare to Phio Pharmaceuticals?

Which has more volatility & risk, GOVX or PHIO?

Do analysts rate GOVX or PHIO?

Which has stronger valuation & earnings, GOVX or PHIO?

Does the media refer more to GOVX or PHIO?

Is GOVX or PHIO more profitable?

Do institutionals and insiders believe in GOVX or PHIO?

Summary

How does GeoVax Labs compare to PDS Biotechnology?

Does the media prefer GOVX or PDSB?

Which has more risk & volatility, GOVX or PDSB?

Is GOVX or PDSB more profitable?

Do analysts prefer GOVX or PDSB?

Do insiders and institutionals believe in GOVX or PDSB?

Which has higher valuation & earnings, GOVX or PDSB?

Summary

How does GeoVax Labs compare to FibroBiologics?

Is GOVX or FBLG more profitable?

Which has more risk and volatility, GOVX or FBLG?

Do insiders & institutionals believe in GOVX or FBLG?

Which has better valuation & earnings, GOVX or FBLG?

Does the media refer more to GOVX or FBLG?

Do analysts prefer GOVX or FBLG?

Summary

How does GeoVax Labs compare to AEON Biopharma?

Does the media prefer GOVX or AEON?

Do institutionals & insiders believe in GOVX or AEON?

Do analysts recommend GOVX or AEON?

Is GOVX or AEON more profitable?

Which has more risk and volatility, GOVX or AEON?

Which has stronger earnings and valuation, GOVX or AEON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX vs. The Competition

GeoVax Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools